Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
AssigneesFormycon AG, Sio2 Medical Products, Inc., Klinge Biopharma GmbH
InventorsCarsten Brockmeyer, Christopher Weikart, Murray Stephen Bennett, Jean-Pierre Giraud, Thomas Strungmann
Life of this patent
Estimating the term…
Abstract
A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.
Claims28
A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, wherein the pre-filled pharmaceutical package comprises:
- a wall comprising a cyclic olefin polymer, having an interior surface enclosing at least a portion of a lumen;
- a tie coating or layer on the wall interior surface comprising SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by X-ray photoelectron spectroscopy (XPS), y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of Rutherford backscattering spectrometry (RBS) or hydrogen forward scattering (HFS);
- a barrier coating or layer of SiOx, in which x is from about 1.5 to about 2.9 as measured by XPS, the barrier coating or layer positioned between the tie coating or layer and the lumen;
- a pH protective coating or layer of SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS, positioned between the barrier coating or layer and the lumen;
- a lubricity coating or layer positioned between the pH protective coating or layer and the lumen, wherein the lubricity coating or layer has the atomic proportions SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS;
- a liquid formulation of a VEGF-antagonist in the lumen;
- and
- a closure closing the lumen;
- wherein the VEGF antagonist is Aflibercept.
-16. (canceled)
-26. (canceled)
(canceled)
-32. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.